Gene Biotherapeutics, Inc. announced on May 22, 2020, Andrew Leitch, John Wallace, Jiayue Zhang and Wei-Wei Zhang resigned from their positions as members of the Company’s Board of Directors. The resignations were required under the terms of the Preferred Stock Purchase Agreement; none of the resigning directors resigned as the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or procedures. Christopher J. Reinhard and Murray Hutchinson each remain a director of the Company. On May 22, 2020, at the request of Nostrum, James Grainer and Kaushik K. Vyas were appointed to the Company’s Board of Directors and James L. Grainer was appointed to serve as Chairman of the Board. James L. Grainer, currently serves as the Chief Financial Officer of Nostrum and its various subsidiaries including Nostrum Laboratories, Inc. Kaushik K. Vyas, currently serves as the Chief Executive Officer of Nostrum Energy, LLC. On May 22, 2020, the individuals have been appointed the executive officers of the Company to serve until the next annual meeting of the Board of Directors and until their successors are duly elected and qualified: Ronald J. Shebuski as Chief Scientific Officer, Lois Chandler as Chief Operating Officer and James L. Grainer as Secretary.